Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
- Sponsor
- Hunan Province Tumor Hospital
- Study ID
- NCT05055947
- Status
- Completed
Conditions
- Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- First line EC/EP+Atezolizumab — DRUGEtoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
Study Details
The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.
Key Dates
- Start date
- Apr 1, 2019
- Status verified
- Apr 2019
- Primary completion
- Jul 1, 2021
- Completion
- Sep 14, 2021
Study Design
- Enrollment
- 60 participants (actual)
Primary Outcome Measure
PFS [ Time Frame: April 2019- July 2021 ]
Related Studies
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerPHASE2 · Recruiting · Muhammad Furqan · Chicago, Illinois
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPHASE2 · Recruiting · Hirva Mamdani · Indianapolis, Indiana
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)PHASE1 · Recruiting · Amgen · Los Angeles, California
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)PHASE1 · Recruiting · Amgen · Gilbert, Arizona